Skip to content

Investigating the effect of consecutive treatment with antibiotics and probiotics in functional flatulence

Comparison of the effectiveness of Probiotics, Metronidazole and Placebo in patients with abdominal flatulence

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230912059417N1
Enrollment
80
Registered
2024-01-09
Start date
2024-01-20
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Flatulence. Flatulence

Interventions

Intervention 1: Intervention group: Patients in this group receive metronidazole 500 mg every 8 hours for 2 weeks. Then regflor probiotic containing 200 mg of active lyophilized Bifidobacterium infect

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 70 years Having functional flatulence (based on Rome III criteria based on history and risk symptoms and functional flatulence diagnostic criteria) Abdominal flatulence feeling at least 3 days a month in the last 3 months The first experience of flatulence is more than 6 months before the study Informed written consent to participate in the study

Exclusion criteria

Exclusion criteria: Any history of chronic inflammatory disease or structural disease of the gastrointestinal tract Any serious physical problem or disease such as inflammation or malignancy Use of calcium channel blocking drugs in the last 3 months Positive family history for colon cancer Celiac disease Any receipt of antibiotics or probiotics 8 weeks before the study Pregnancy or breastfeeding alcohol consumption

Design outcomes

Primary

MeasureTime frame
Bloating severity score. Timepoint: Before of the intervention, 2, 4, 6 and 8 weeks after the start of the study. Method of measurement: Questionnaire IBS- QOL.;Quality of life. Timepoint: Before of the intervention, 2, 4, 6 and 8 weeks after the start of the study. Method of measurement: Questionnaire IBS- QOL.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Tabesh

Esfahan University of Medical Sciences

tabesh.elham@med.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026